<DOC>
	<DOCNO>NCT02180113</DOCNO>
	<brief_summary>FibroScan® ( Echosens , Paris , France ) active non implantable medical device market Europe since December 2003 currently use many country . FibroScan® ultrasound-based vibration-controlled transient elastography ( VCTE™ ) device dedicate liver stiffness measurement ( LSM ) . Several clinical study show accuracy LSM FibroScan® predict liver fibrosis . Some study already show good correlation LSM , assess FibroScan® base VCTE™ technology , presence portal hypertension ( PHT ) . PHT clinical condition characterize high blood pressure portal vein tributary define gradient portal systemic blood pressure &gt; 6 mmHg . The development oesophageal varix ( OV ) cirrhotic patient , well potential bleeding , represent one severe life-threatening complication cirrhosis . Upper endoscopy best diagnostic tool detect presence OV , gastric varix congestive gastropathy , estimate grade OV recognition presence red color sign wale mark indicator high risk bleeding . However two method quite invasive associated risk ; time , cirrhotic patient present OV endoscopic screening . The aim study validation SSM , assess FibroScan® acquisition parameter algorithm optimize SSM , surrogate noninvasive marker presence OV liver cirrhosis patient .</brief_summary>
	<brief_title>Spleen Stiffness Measurement With FibroScan</brief_title>
	<detailed_description />
	<criteria>All group Both gender , 1879 year old Patient able give write informed consent form Patient affiliate social security system . Case group Patient chronic liver disease due : hepatitis C virus , hepatitis B virus Alcoholic Liver Disease liver stiffness ≥ 14 kPa Patient follow examination within 3 month LSM SSM : ultrasound examination , blood examination , gastroscopy examination eventually hepatic venous pressure gradient examination Control group Patient chronic liver disease due : HCV , HBV Alcoholic Liver Disease liver stiffness &lt; 14 kPa Patients without chronic liver disease ( Healthy Control subgroup ) Patient unable unwilling provide write informed consent . Consuming illness ( HIV infection , malignancy ) . Associated comorbidities : NASH , hemochromatosis , primary sclerosing cholangitis , primary biliary cirrhosis . Antiviral treatment two month inclusion . Pacemaker heart defibrillator . Pregnancy . Liver transplantation . BMI &gt; 35 kg/m2 . Serum Transaminases &gt; 250 IU/L . History / current βblockers treatment OV . Presence ascites . Previous endoscopic treatment OV . Patient acute alcoholic hepatitis associate jaundice ( generally define total bilirubin ≥ 50 µmol/l ) . Patient hepatocellular carcinoma ( HCC ) . Unable unwilling undergo liver stiffness measurement , spleen stiffness measurement , ultrasound examination , blood examination gastroscopy examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cirrhotic patient</keyword>
	<keyword>Fibroscan</keyword>
	<keyword>Liver Stiffness Measurement</keyword>
	<keyword>Oesophageal Varices</keyword>
	<keyword>Portal Hypertension</keyword>
	<keyword>Spleen Stiffness Measurement</keyword>
</DOC>